196 related articles for article (PubMed ID: 30003374)
1. Unintended consequences of decreased PSA-based prostate cancer screening.
Ahlering T; Huynh LM; Kaler KS; Williams S; Osann K; Joseph J; Lee D; Davis JW; Abaza R; Kaouk J; Patel V; Kim IY; Porter J; Hu JC
World J Urol; 2019 Mar; 37(3):489-496. PubMed ID: 30003374
[TBL] [Abstract][Full Text] [Related]
2. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
3. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
4. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
5. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
Freedland SJ; Aronson WJ; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Terris MK;
Urology; 2003 Apr; 61(4):742-7. PubMed ID: 12670558
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.
Tilki D; Schlenker B; John M; Buchner A; Stanislaus P; Gratzke C; Karl A; Tan GY; Ergün S; Tewari AK; Stief CG; Seitz M; Reich O
Urol Oncol; 2011; 29(5):508-14. PubMed ID: 19837614
[TBL] [Abstract][Full Text] [Related]
7. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
[TBL] [Abstract][Full Text] [Related]
8. Small-volume lymph node involvement and biochemical recurrence after robot-assisted radical prostatectomy with extended lymph node dissection in prostate cancer.
Morizane S; Honda M; Shimizu R; Teraoka S; Nishikawa R; Tsounapi P; Kimura Y; Iwamoto H; Hikita K; Takenaka A
Int J Clin Oncol; 2020 Jul; 25(7):1398-1404. PubMed ID: 32333202
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment tables predicting pathologic stage of locally advanced prostate cancer.
Joniau S; Spahn M; Briganti A; Gandaglia G; Tombal B; Tosco L; Marchioro G; Hsu CY; Walz J; Kneitz B; Bader P; Frohneberg D; Tizzani A; Graefen M; van Cangh P; Karnes RJ; Montorsi F; van Poppel H; Gontero P;
Eur Urol; 2015 Feb; 67(2):319-25. PubMed ID: 24684960
[TBL] [Abstract][Full Text] [Related]
10. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
[TBL] [Abstract][Full Text] [Related]
11. Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice.
Gaylis FD; Choi JE; Hamilton Z; Dato P; Cohen E; Calabrese R; Prime H; Rosenbaum A; Kader AK
Urol Oncol; 2017 Nov; 35(11):663.e1-663.e7. PubMed ID: 28736250
[TBL] [Abstract][Full Text] [Related]
12. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
[TBL] [Abstract][Full Text] [Related]
13. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
[TBL] [Abstract][Full Text] [Related]
14. Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men.
Assel MJ; Ulmert HD; Karnes RJ; Boorjian SA; Hillman DW; Vickers AJ; Klee GG; Lilja H
Prostate; 2020 Jan; 80(1):51-56. PubMed ID: 31603253
[TBL] [Abstract][Full Text] [Related]
15. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
16. [-2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report.
De Luca S; Passera R; Sottile A; Fiori C; Scarpa RM; Porpiglia F
BMC Urol; 2016 Mar; 16():14. PubMed ID: 27013515
[TBL] [Abstract][Full Text] [Related]
17. Lymph node yield during radical prostatectomy does not impact rate of biochemical recurrence in patients with seminal vesicle invasion and node-negative disease.
Badani KK; Reddy BN; Moskowitz EJ; Paulucci DJ; Beksac AT; Martini A; Whalen MJ; Skarecky DW; Huynh LM; Ahlering TE
Urol Oncol; 2018 Jun; 36(6):310.e1-310.e6. PubMed ID: 29625782
[TBL] [Abstract][Full Text] [Related]
18. Changes in prostate cancer at radical prostatectomy during the prostate specific antigen era: an Italian experience.
Bollito E; Terrone C; Volpe A; Porpiglia F; Cracco C; Poggio M; Grande S; Righi L; Bellina M; Papotti M; Scarpa RM
Anal Quant Cytol Histol; 2008 Jun; 30(3):152-9. PubMed ID: 18630840
[TBL] [Abstract][Full Text] [Related]
19. The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
Zargar H; van den Bergh R; Moon D; Lawrentschuk N; Costello A; Murphy D
BJU Int; 2017 Jan; 119(1):110-115. PubMed ID: 27454454
[TBL] [Abstract][Full Text] [Related]
20. Trends in clinical and oncological outcomes of robot-assisted radical prostatectomy before and after the 2012 US Preventive Services Task Force recommendation against PSA screening: a decade of experience.
Seetharam Bhat KR; Moschovas MC; Onol FF; Sandri M; Rogers T; Roof S; Rocco B; Patel VR
BJU Int; 2020 Jun; 125(6):884-892. PubMed ID: 32173990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
